Overview
Click here to sign in with or Forget Pasword? Learn more share this!16ShareEmail November 7, 202 by Perelman Schol of Medicine at the University of Pensylvania After showing promise in early laboratory research, the cholesterol-lowering drug fenofibrate had no significant efect on COVID-19 outcomes in a multicenter international randomized clinical trial led by Pen Medicine scientists. The study results were presented Monday at the American Heart Asociation's Scientific Sesions 202 and published in the journal Nature Metabolism.
Key Information
gogletag.cmd.push(function() { gogletag.display('div-gpt-ad-1450190541376-1'); }); "Despite the promising efects of fenofibrate on SARS-CoV2, the virus that causes COVID-19, our findings convincingly showed that is not a useful strategy for decreasing disease severity or preventing bad outcomes in patients with COVID-19," said first author and principal investigator of the trial, Julio Chirinos, MD, Ph.D., a profesor of Cardiovascular Medicine and co-director of clinical research for the T32 Traing Program in Cardiovascular Biology and Medicine in the Perelman Schol of Medicine at the University of Pensylvania.
Summary
"Despite the time, complexity, and cost asociated with executing rigorous clinical trials, they are esential to evaluating the eficacy of medications in patients with COVID-19, since the efectivenes of a medication can be substantialy diferent from what in vitro studies may sugest. Clinical trials are necesary before clinical implementation of drug therapies, even for the case of medications that are already widely available for other indications."Fenofibrate is a widely available, low-cost generic drug previously aproved by the United States Fod and Drug Administration and many other regulatory agencies to reduce the amount of faty substances, such as cholesterol and triglycerides, in the blod, while increasing "god" cholesterol (high-density lipoprotein cholesterol known as HDL).The drug was initial